## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)		1												
Name and Address of Reporting Person * Lucido Louis C.					2. Issuer Name <b>and</b> Ticker or Trading Symbol BioCorRx Inc. [BICX]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner				
(Last) (First) (Middle) 2390 EAST ORANGEWOOD AVENUE, SUITE 575				3. Date of Earliest Transaction (Month/Day/Year) 03/31-05:00/2020							Office	r (give title belo	ow)	Other (specify	pelow)	
(Street) ANAHEIM, CA 92806				4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line)  _X_ Form filed by One Reporting Person  Form filed by More than One Reporting Person					
(City) (State) (Zip)				Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												
(Instr. 3) Da			Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)		(Instr. 8)		4. Securities Acqu (A) or Disposed o (Instr. 3, 4 and 5)		f (D) Beneficia Reported		nt of Securities ally Owned Following Transaction(s)		Ownership Form:	Beneficial	
						ode	V	Amoun	(A) or (D)	Price	(Instr. 3 a	nd 4)		Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)	
		03/31- 05:00/2020			Α	(1)	2	2,641	A	\$ 0	252,633			D		
			Table II -				t	the for d, Disp	rm dis	splays a c	urrer eficiall	ntly valid		spond unle trol numbe		
1. Title of	2.	3. Transaction		(e.g., puts,		arran 5.				tible secur	T	tle and	8. Price of	9. Number	of 10.	11. Natur
Derivative Security	Conversion or Exercise Price of Derivative Security	Date (Month/Day/\)		Code (Instr. 8)		Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		and Expiration Date (Month/Day/Year)		Amount of Underlying Securities (Instr. 3 and 4)		Derivative Security (Instr. 5)	Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Owners Form o Derivat Security Direct ( or Indir	hip of Indirect Beneficial Ownersh (Instr. 4)	
				Co	ode V	(A)		Date Exerci		Expiration Date	Title	Amount or Number of Shares				
Repor	ting O	wners														

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Lucido Louis C. 2390 EAST ORANGEWOOD AVENUE SUITE 575 ANAHEIM, CA 92806	X					

# **Signatures**

/s/ Louis Lucido	04/02-05:00/2020
***Signature of Reporting Person	Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- These shares were issued to Mr. Lucido pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Lucido. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to \$5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was \$1.89.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.